Molecular Assessment of Lymph Nodes in Patients With Resected (Stage I to IIIA) Non-small Cell Lung Cancer
NCT ID: NCT00213733
Last Updated: 2011-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2004-06-30
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Signature From Tumor to Lymph Nodes
NCT04677205
Surgical Versus Non-surgical Staging of Lung Cancer
NCT01117714
Prognostic Significance of the Uncertain Resection in NSCLC
NCT06511661
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
NCT06252129
A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
NCT05732974
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent is required.
Exclusion Criteria
* Chemotherapy before surgical treatment
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospital, Strasbourg, France
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michèle BEAU-FALLER, MD
Role: PRINCIPAL_INVESTIGATOR
Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital de Hautepierre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Chirurgie Thoracique, Hôpital Civil
Strasbourg, , France
Service de Pneumologie, Hôpital Lyautey
Strasbourg, , France
Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital de Hautepierre
Strasbourg, , France
Service d'Anatomie Pathologique, Hôpital de Hautepierre
Strasbourg, , France
Service de Pneumologie, Hôpital de Hautepierre
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3207
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.